en · de · es · pt
cardarine-notes.peptides6823.com › Data › Cardarine As Investigational Pparδ Agonist — Background and Details

Cardarine As Investigational Pparδ Agonist — Background and Details

By Editorial Desk · published 2026-06-30 · last reviewed 2026-08-01 · Data

This is a working overview of PPARδ agonist, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Cardarine as Investigational PPARδ Agonist

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Identity and Regulatory Status

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516, GW-501516, GW 501516, endurobolNames vary in research and anti-doping documents.
Chemical classSynthetic PPARδ agonistSmall-molecule nuclear receptor ligand.
CAS Registry Number317318-70-0Identifier commonly associated with GW501516.
AppearanceWhite to off-white powderTypical for purified research material.
SolubilityLow in water; soluble in DMSO and ethanolOrganic solvents are common for laboratory stock solutions.

Background and Regulatory Status

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.

Related pages on this site

Detection and Regulatory Landscape

A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.

Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.

Regulation and Analytical Detection

Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.

Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.

Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.

Preclinical Findings and Safety Signals

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Supporting material

The diagnosis of methemoglobinemia is made with the typical symptoms, a suggestive history, low oxygen saturation on pulse oximetry measurements (SpO2) and these symptoms (cyanosis and hypoxia) failing to improve on oxygen treatment. The definitive test would be obtaining either CO-oximeter or a methemoglobin level on an arterial blood gas test. Arterial blood with an elevated methemoglobin level has a characteristic chocolate-brown color as compared to normal bright red oxygen-containing arterial blood; the color can be compared with reference charts. The SaO2 calculation in the arterial blood gas analysis is falsely normal, as it is calculated under the premise of hemoglobin either being oxyhemoglobin or deoxyhemoglobin. However, co-oximetry can distinguish the methemoglobin concentration and percentage of hemoglobin. At the same time, the SpO2 concentration as measured by pulse ox is false high, because methemoglobin absorbs the pulse ox light at the 2 wavelengths it uses to calculate the ratio of oxyhemoglobin and deoxyhemoglobin. For example with a methemoglobin level of 30–35%, this ratio of light absorbance is 1.0, which translates into a false high SpO2 of 85%.

Archival Resources Details Thorburn Brailsford Robertson: Repository: Commonwealth Scientific and Industrial Research Organisation (CSIRO) Corporate Records and Archives Strategies, The Encyclopedia of Australian Science and Innovation. Robertson, Thorburn Brailsford (1884–1930), The Encyclopedia of Australian Science and Innovation. Thorburn Brailsford Robertson, Adelaide Connect, University of Adelaide. Lehmann Jayne, "World Diabetes Day – Time to celebrate Adelaide’s link to 1922 insulin discovery", EdHealth Australia, 14 November 2016. Thorburn Brailsford Robertson, South Australian Medical Heritage Society. TROVE: "From the library of Thorburn Brailsford Robertson".

In Brazil, the Aeronautical Accidents Investigation and Prevention Center (CENIPA) was established under the auspices of the Aeronautical Accident Investigation and Prevention Center, a Military Organization of the Brazilian Air Force (FAB). The organization is responsible for the activities of aircraft accident prevention, and investigation of civil and military aviation occurrences. Formed in 1971, and in accordance with international standards, CENIPA represented a new philosophy: investigations are conducted with the sole purpose of promoting the "prevention of aeronautical accidents". In Canada, the Transportation Safety Board of Canada (TSB), is an independent agency responsible for the advancement of transportation safety through the investigation and reporting of accident and incident occurrences in all prevalent Canadian modes of transportation – marine, air, rail and pipeline. In China, the Civil Aviation Administration of China (CAAC) is solely responsible for all air investigations and safety inside the country after the split from the formal CAAC Airlines.

Aldo-keto reductase family 1 (AKR1) is a family of aldo-keto reductase enzymes that is involved in steroid metabolism. It includes the AKR1C and AKR1D subgroups, which respectively consist of AKR1C1–AKR1C4 and AKR1D1. Together with short-chain dehydrogenase/reductases (SDRs), these enzymes catalyze oxidoreductions, act on the C3, C5, C11, C17 and C20 positions of steroids, and function as 3α-HSDTooltip 3α-Hydroxysteroid dehydrogenases, 3β-HSDsTooltip 3β-Hydroxysteroid dehydrogenases, 5β-reductases, 11β-HSDsTooltip 11β-Hydroxysteroid dehydrogenases, 17β-HSDsTooltip 17β-hydroxysteroid dehydrogenases, and 20α-HSDsTooltip 20α-Hydroxysteroid dehydrogenases, respectively. The AKR1C enzymes act as 3-, 17- and 20-ketosteroid reductases, while AKR1D1 acts as the sole 5β-reductase in humans. AKR1A1; AKR1B1; AKR1B10; AKR1C1; AKR1C2; AKR1C3; AKR1C4; AKR1D1; Others Steroidogenic enzyme

Sources: en.wikipedia.org

Notes from published material

argon (E938), a inert gas used for canned products helium (E939), a inert gas used for canned products nitrogen (E941), a nonreactive packaging gas and propellant carbon dioxide (E290), a nonreactive packaging gas and propellant Specific kinds of packaging gases are aerosol propellants. These process and assist the ejection of the product from its container. chlorofluorocarbons known as CFC (E940 and E945), now rarely used because of the damage that they do to the ozone layer: dichlorodifluoromethane (E940) chloropentafluoroethane (E945) nitrous oxide (E942), used for aerosol whipped cream canisters (see Nitrous oxide: Aerosol propellant) octafluorocyclobutane (E946) These must be used with caution as they may have adverse effects when exposed to certain chemicals. They will cause oxidisation or contamination to certain types of materials. oxygen (E948), used e.g. for packaging of vegetables hydrogen (E949)

They Hunger is a single player horror-based mod of Valve's first-person shooter Half-Life. It was released by Neil Manke's Black Widow Games in three episodes, They Hunger (2000), They Hunger 2: Rest in Pieces (2000), and They Hunger 3: Rude Awakening (2001). All three episodes were sponsored by PC Gamer and appeared on the magazine's cover disk. The original mod received positive reviews from critics; who commended the project's quality, horror elements, and the way it used the GoldSrc engine. A fourth game made for the Source engine, They Hunger: Lost Souls, was cancelled.

In 2019, the European Commission announced that CBD and other cannabinoids would be classified as "novel foods", meaning that CBD products would require authorization under the EU Novel Food Regulation stating that because "this product was not used as a food or food ingredient before May 15, 1997, before it may be placed on the market in the EU as a food or food ingredient, a safety assessment under the Novel Food Regulation is required." The recommendation – applying to CBD extracts, synthesized CBD, and all CBD products, including CBD oil – was scheduled for a final ruling by the European Commission in March 2019. If approved, manufacturers of CBD products would be required to conduct safety tests and prove safe consumption, indicating that CBD products would not be eligible for legal commerce until at least 2021. In December 2020, the European Commission concluded that CBD should not be considered as drug and can be qualified as food. Cannabidiol is listed in the EU Cosmetics Ingredient Database (CosIng). However, the listing of an ingredient, assigned with an INCI name, in CosIng does not mean it is to be used in cosmetic products or is approved for such use. Several industrial hemp varieties can be legally cultivated in Western Europe. A variety such as "Fedora 17" has a cannabinoid profile consistently around 1%, with THC less than 0.3%.

where E is the Young's modulus, ν is Poisson's ratio, and KI is the stress intensity factor in mode I. Irwin also showed that the strain energy release rate of a planar crack in a linear elastic body can be expressed in terms of the mode I, mode II (sliding mode), and mode III (tearing mode) stress intensity factors for the most general loading conditions. Next, Irwin adopted the additional assumption that the size and shape of the energy dissipation zone remains approximately constant during brittle fracture. This assumption suggests that the energy needed to create a unit fracture surface is a constant that depends only on the material. This new material property was given the name fracture toughness and designated GIc. Today, it is the critical stress intensity factor KIc, found in the plane strain condition, which is accepted as the defining property in linear elastic fracture mechanics.

=== Cancer === In a 2022 update of an earlier report, the United States Preventive Services Task Force recommended against the use of vitamin E supplements for the prevention of cardiovascular disease or cancer, concluding there was insufficient evidence to assess the balance of benefits and harms, yet also concluding with moderate certainty that there is no net benefit of supplementation. As for literature on different types of cancer, an inverse relationship between dietary vitamin E and kidney cancer and bladder cancer is seen in observational studies. A large clinical trial reported no difference in bladder cancer cases between treatment and placebo. An inverse relationship between dietary vitamin E and lung cancer was reported in observational studies, but a large clinical trial in male tobacco smokers reported no impact on lung cancer between treatment and placebo, and a trial which tracked people who chose to consume a vitamin E dietary supplement reported an increased risk of lung cancer for those consuming more than 215 mg/day. For prostate cancer, there are also conflicting results. A meta-analysis based on serum alpha-tocopherol content reported an inverse correlation in relative risk, but a second meta-analysis of observational studies reported no such relationship. A large clinical trial with male tobacco smokers and reported a 32% decrease in the incidence of prostate cancer, but the SELECT trial of selenium or vitamin E for prostate cancer enrolled men ages 55 or older and reported relative risk 17% higher for the vitamin group.

Sources: en.wikipedia.org

Background from the literature

Jaquelyn Patricia Longworth, Operational Safety and Policy Manager, Nuclear Electric Ltd. For services to Engineering Management. Walter Herbert Love. For services to Radio Journalism. Maurice Ernest Lowe, Engineering Manager, Vosper Thornycroft (UK) Ltd. For services to the Defence Industry. William Lowe. For services to the Library Service. June Valerie Lucas. For services to the community in Stanford Rivers, Essex. Brenda Germaine Lynn, Sub Divisional Officer, Special Constabulary, West Yorkshire Police. For services to the Police. Monica Lynskey, lately Administrative Officer, Office for Standards in Education. James Archibald MacDonald, Head Greenkeeper, Royal Lytham & St Annes Golf Club. For services to Golf. Thomas MacDougall, Retained Sub-Officer, Tayside Fire Brigade. For services to the Fire Service. Williamina MacGregor, School Cook, Lochardil Primary School, Inverness. For services to Education. Jean Macinnes. For services to the Citizens' Advice Bureau in Aberdeen. Laurence Macintyre, Chief Superintendent, Strathclyde Police. For services to the Police. John Kenneth MacKay, Crofter. For services to the community in Sutherlandshire. John Watson Mackay, Head of Recreation and Access Branch, Research and Advisory Services, Directorate, Scottish Natural Heritage. For services to Countryside Recreation. Florence King MacKenzie, Director, Scottish Churches Architectural Heritage Trust. For services to the Restoration of Church Buildings. George MacLean, lately Manager, Air Traffic Service, Sumburgh Airport (Shetland), Civil Aviation Authority.

=== Chairmen === R.S. Sharma, 1972 - 1977 A.R. Kulkarni, 1978 - 1981 Niharranjan Ray, 1981 - 1981 Lokesh Chandra, 1982 - 1985 Irfan Habib, 1986 - 1993 Ravinder Kumar, 1993 - 1996 S. Settar, 1996 - 1999 K.S. Sarma (acting), 1999 - 1999 B.R. Grover, 1999 - 2001 K.S. Lal, 2001 - 2001 M.G.S. Narayanan, 2001 - 2003 Kumud Bansal (acting), 2003 - 2004 D.N. Tripathi, 2004 - 2007 K.M. Acharya (acting), 2007 - 2007 Sabyasachi Bhattacharya, 4 March 2007 – 3 March 2010 Sabyasachi Bhattacharya (acting), 4 April 2010 – 20 May 2011 Basudev Chatterjee, 20 May 2011 - 2014 Yellapragada Sudershan Rao, 28 June 2014 - 26 June 2017 A.P Jamkhedkar, 15 February 2018 – 14 January 2022 Raghuvendra Tanwar, 14 January 2022 - present

=== Chemically modified dextran microspheres === Microspheres can also be developed by chemically modifying dextran. Acetated dextran can be modified with amine groups and grafted with heparin to form microspheres that provide protamine-stimulated, targeted drug release for the delivery of therapeutics to treat cardiovascular diseases. Dextran modified with an octyl- group creates microspheres that provide extended release of doxorubicin, which is an antitumor therapeutic.

==== Traumatic calcinosis cutis ==== Traumatic calcinosis cutis is a cutaneous condition characterized by calcification of the skin resulting from the deposition of calcium and phosphorus often resulting from occupational exposure, as in cases reported in oil-field workers and coal miners.

Increased body temperature >38 °C (>100.4 °F) Confused or altered consciousness Excessive sweating Severely rigid muscles Autonomic imbalance The first symptoms of neuroleptic malignant syndrome are usually muscle cramps and tremors, fever, symptoms of autonomic nervous system instability such as unstable blood pressure, and sudden changes in mental status (agitation, delirium, or coma). Other possible symptoms include sweating, trouble swallowing, incontinence, and mutism. Once symptoms appear, they may progress rapidly and reach peak intensity in as little as three days. These symptoms can last anywhere from eight hours to forty days, with the median duration of symptoms, with treatment, being nine days. The median onset of symptoms is four days after initiating the offending medication, but in some cases symptoms may begin up to 30 days later. Symptoms are sometimes misinterpreted by doctors as symptoms of mental illness which can result in delayed treatment. Symptoms may also be mistaken for similarly presenting conditions such as malignant hyperthermia, serotonin syndrome, and substance intoxication from illicit drugs such as cocaine, methamphetamine, or MDMA. Neuroleptic malignant syndrome (NMS) usually presents with a "lead pipe rigidity" in which the muscles are stiffened and resistance is observed throughout the range of motion on testing. Severe cases may present as catatonia in which the person is not responsive to stimuli. The deep tendon reflexes in NMS are usually preserved whereas serotonin syndrome presents with myoclonus or hyperactive muscle reflexes.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Is cardarine a steroid?

No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.

Why was cardarine not developed further?

Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.

Is cardarine a SARM?

No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.

Network